Clinical Trials Logo

B-Cell Neoplasm clinical trials

View clinical trials related to B-Cell Neoplasm.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04665115 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Start date: November 23, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effects of ibrutinib in treating patients with B-cell malignancies who are infected with COVID-19. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ibrutinib is a first in class Bruton tyrosine kinase inhibitor (BTKi), for the treatment of B-cell malignancies. This study is being done to determine if taking ibrutinib after contracting COVID-19 will make symptoms better or worse.